Read by QxMD icon Read


M Sarkar, B K Dutta Borah, B S Prakash
An attempt was undertaken to investigate the efficacy of Ovsynch protocol for timed artificial insemination (TAI) with or without Norprolac (antiprolactin) treatment during non-breeding season (winter months) in yaks (n = 25). During non-breeding season, plasma prolactin profile has been reported high due to cold and nutritional stress. The Norprolac dose of i.m. administration was standardized for prolactin suppression. Three different doses viz. 2.5, 5.0 and 7.5 mg were attempted and the dose of 7.5 mg Norprolac i...
June 2010: Reproduction in Domestic Animals, Zuchthygiene
K S Roy, B S Prakash
The aim of this study was to compare the changes in hormonal profiles during ovsynch and ovsynch plus norprolac treatment in Murrah buffalo heifers following timed artificial insemination (TAI) at stressful summer months, through intensive endocrine analysis. The norprolac (an anti-prolactin drug) at the dose rate of 10.0 mg/animal /day effectively suppressed the level of prolactin upto 30 hours. The hormones quantified in blood plasma samples collected before, during and after ovsynch and ovsynch plus norprolac treatment were LH, prolactin, progesterone, estradiol-17beta and total estrogens...
April 2009: Tropical Animal Health and Production
K S Roy, B S Prakash
The objectives of this study were to establish the characteristics of oestrous behaviour in Ovsynch (induction of ovulation through administration of GnRH-PGF2-GnRH in a systemic manner on 0, seventh and ninth day respectively) and Ovsynch plus Norprolac (Quinagolide hydrochloride – an inhibitor of prolactin secretion) treated Murrah buffalo heifers and to determine the relationships between this behaviour and the plasma concentrations of oestradiol-17β (E2), total oestrogen, and progesterone. Oestrus was detected by visual observations of oestrus signs, per rectal examination of genitalia and bull parading thrice a day during treatment period...
August 2009: Journal of Animal Physiology and Animal Nutrition
K S Roy, B S Prakash
A simple and highly sensitive enzyme immunoassay (EIA) was developed and validated for prolactin quantification in buffalo plasma (on a microtitreplate) using the biotin-streptavidin-peroxidase amplification and immobilized antiserum in a competitive assay. Prolactin standards (range: 5-5000 pg/(well 50 microL)) were prepared in hormone-free plasma collected from minimal stress non-lactating buffalo heifers in temperate weather. The sensitivity of the EIA procedure was 5 pg/(well 50 microL) (corresponds to 0...
February 2007: Theriogenology
P N Schultz, L Ginsberg, I E McCutcheon, N Samaan, M Leavens, R F Gagel
OBJECTIVE: This study reports a six year experience with quinagolide (CV205-502) in the treatment of 40 patients with hyperprolactinemia or prolactinoma. PATIENTS AND MEASUREMENTS: Forty patients with hyperprolactinemia were treated with quinagolide (CV 205-502, Norprolac) for 2-72 months (mean 31.6 months). The patient's ages ranged from 12 to 53 years and 90% were female. Seventeen had no radiologic evidence of tumor; 11 had microadenomas; and 12 had macroadenomas...
December 2000: Pituitary
A Hrycek, P Cieślik, J Tustanowski, S Nowak, P Jedynak
The objective of this study was to determine the effect of quinagolide (Norprolac) on serum level of cytokines in systemic lupus erythematosus (SLE) patients. In 20 SLE patients treated with a low dose of quinagolide, and in 17 healthy persons who constituted the control group, concentration of serum prolactin (PRL), interleukins (ILs), soluble tumor necrosis factor receptors (sTNF Rs) preceded by calculation of disease activity index (SLEDAI) were tested at entry and then after 3 months in 16 patients and after 6 months in 11 patients who completed the study...
2001: Lupus
V Rohmer, E Freneau, I Morange, C Simonetta
OBJECTIVE: A retrospective French multicenter analysis was carried out to assess changes in tumor volume and plasma prolactin concentration in order to evaluate the efficacy of quinagolide (Norprolac) in patients with prolactinoma resistant to ergot dopamine agonists. PATIENTS AND METHODS: One hundred seven patients (46 men and 61 women) from 27 centers were included in the statistical analysis. All had previously been treated with a dopamine agonist (bromocriptine)...
November 2000: Annales D'endocrinologie
J Dudkiewicz, D Grzonka, M Czarnecki
OBJECTIVES AND DESIGN: The aim of study was evaluation of three methods of treatment of functional, evident hyperprolactinemia in women with primary or secondary sterility by use of Bromoergocriptine, Dopergin or Norprolac. MATERIALS AND METHODS: Our study contained 65 patients divided into three groups treated by use three methods. We used RIA-method for evaluation serum concentrations of h-PRL. Authors estimated the impact of dopaminergic receptors D2 agonist on the serum concentrations of h-PRL before, in 2nd and 6th month of observation...
December 1998: Ginekologia Polska
A Tabarin, B Catargi
Quinagolide is a non-ergot dopaminergic agonist recently available on the French market. The endocrine and tumoral efficacy as well as the safety and tolerability of quinagolide in the treatment of macroprolactinomas are reviewed. In this situation, plasma prolactin levels are normalized in about 60% of patients and in about one third of those who are resistant to bromocriptine. A significant decrease in pituitary tumor size is demonstrated by radiographic studies in 58 to 69% of patients. About one third of patients show more than 50% tumor shrinkage...
1997: Annales D'endocrinologie
L Vilar, C W Burke
OBJECTIVE: To audit the efficacy of quinagolide (CV205-502, Norprolac, Sandoz) in lowering prolactin, and its tolerability, in patients with bromocriptine resistance (BCR) or bromocriptine intolerance (BCI), in view of the paucity of results published in patients specifically with BCR or BCI, by collating results in our own patients with the reports in the literature. DESIGN: Open prospective, uncontrolled administration of quinagolide in patients with BCR (defined for this report as failure to attain normal prolactin levels after 4 months of bromocriptine at maximum tolerated doses), or BCI (defined as a patient request to cease bromocriptine treatment because of side-effects at doses that were required, or failed, to normalize PRL levels)...
December 1994: Clinical Endocrinology
(no author information available yet)
In 1976 we heralded the introduction of bromocriptine (Parlodel-Sandoz) as "an important advance" for the treatment of patients with hyperprolactinaemia. Now two new drugs are available for treating hyperprolactinaemia; cabergoline (Dostinex-Pharmacia) which the manufacturer claims offers "a significant advance in prolactin control" and quinagolide (Norprolac-Sandoz) for which the claim is of a "significant advance in the therapy of hyperprolactinaemia". Do these newer products hold real advantages?
September 1995: Drug and Therapeutics Bulletin
D E Prentice, A W Meikle
This paper describes control of normal Leydig cell function and testosterone production. The macroscopic and histopathological appearances of spontaneous Leydig cell hyperplasias and tumors (LCT) in the rat are reviewed together with their incidence and hormonal status. Drugs which induce LCTs in chronic studies are discussed and include busereline, carbamazepine, cimetidine, finasteride, flutamide, gemfibrozil, histrelin, hydralazine, indomethacin, isradipine, lactitol, leuprolide, metronidazole, mesulergine, nafarelin, norprolac and vidarabine...
July 1995: Human & Experimental Toxicology
C Rasmussen, J Brownell, T Bergh
Twenty-four hyperprolactinemic women of whom 23 previously had been given bromocriptine, were treated between 6 and 24 months with a new non-ergot dopamine agonist, CV 205-502 (quinagolide; Norprolac, Sandoz Ltd, Basle Switzerland). Twenty-four weeks of treatment resulted in normalization of prolactin secretion in 16 of the 24 women. All of these women as well as 4 of those who remained hyperprolactinemic had regular menstrual bleedings. Fifteen of the 24 women were treated for 24 months and all had normalized prolactin levels in serum at the end of this period...
August 1991: Acta Endocrinologica
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"